For over 26 years, Cancer Research for the Ozarks (CRO) has provided access to NCI-approved clinical trials to the rural communities of southwestern Missouri and surrounding areas through the Community Clinical Program. CRO is eager to transition to an NCI Community Oncology Research Program (NCORP) Community Site and expand access throughout south, central, and eastern Missouri as well as southern Illinois. During the past five years, CRO has added five components expanding to a population that spans central and eastern Missouri, and southern Illinois. Through the visionary leadership of its outstanding Principal Investigators including current Principal Investigator, Jay Carlson, DO, this largely rural population to NCI (NCORP). From its inception, CRO has had the support of the two nationally recognized health care systems, CoxHealth and Mercy Hospital Springfield in Springfield, Missouri providing a unique opportunity to change a wide community of practice. CRO has available access to an extensive network of non-oncology physicians and other medical professionals including geneticists as well as a broad network of community service providers. Based on its experience and expansion, CRO is confident it can secure over 200 accruals and credits per year in cancer treatment, prevention, and control. CRO is enthusiastic about the realignment of scope in research trials including expanded plans for cancer prevention and control. CRO fully supports new NCORP priorities to address cancer care delivery and disparities are consistent with ongoing efforts to improve access, service delivery, and outcomes at all CRO components.

Public Health Relevance

CRO provides the sole access to NCI-sponsored cancer clinical trials for a large number of individuals living in southern Missouri and surrounding area. Although relatively homogeneous, the population has a disproportionate share of families in poverty and a population at higher risk for poor health outcomes. The CRO NCORP Community Site will use an extensive community network to increase access and ultimately, improve practice and outcomes.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RTRB-E (M1))
Program Officer
Mccaskill-Stevens, Worta J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ozark Health Ventures, LLC
United States
Zip Code
Ahmed, Amina; Deng, Wei; Tew, William et al. (2018) Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study. Gynecol Oncol 150:300-305
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Wagner, Lynne I; Zhao, Fengmin; Goss, Paul E et al. (2018) Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG Breast Cancer Res Treat 169:537-548
Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493
Aghajanian, Carol; Filiaci, Virginia; Dizon, Don S et al. (2018) A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol 150:274-281
Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703
Chan, John K; Deng, Wei; Higgins, Robert V et al. (2017) A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 146:554-559
Chung, Vincent; McDonough, Shannon; Philip, Philip A et al. (2017) Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol 3:516-522

Showing the most recent 10 out of 16 publications